Two pivotal phase III trials, SPOTLIGHT and GLOW, have established the clinical benefit of adding zolbetuximab to first-line chemotherapy in patients with CLDN18.2-positive, HER2-negative advanced GI or GEJ adenocarcinoma [141,142]. The gene discussed is ERBB2; the disease is gastroesophageal junction adenocarcinoma.